XXXX : A 15-Year Experience of a Single Center With the MSKCC P6 Treatment Protocol.

@entity1 @entity2828 @entity66 @entity8253 @entity3478 @entity5
INTRODUCTION: @entity2828 ( @entity2828 ) is the second most common @entity3478 in @entity1 . Current chemotherapeutic regimens include high-dose @entity8253 and alkylating agents with significant variation in treatment length. The Memorial Sloan Kettering Cancer Center P6 regimen (MSKCC P6) treatment protocol is a highly aggressive regimen given over 21 weeks only. We present the outcome of @entity2828 @entity1 treated in our center with this protocol over the last 15 years. PROCEDURE: We retrospectively analyzed data on the presentation, @entity1 characteristics, treatment, and outcome of all @entity2828 @entity1 treated according to the MSKCC P6 regimen from 1999 to 2014. RESULTS: Of 48 @entity1 , 37 (77%) presented with a nonmetastatic disease and 26 (54%) with @entity5 located in the extremities. The 5-year overall survival (OS) of the entire cohort was 55.9%  8%. @entity66 conferred a better prognosis with a 5-year OS of 68.4%  8.5%. @entity1 with a nonmetastatic extremity @entity5 had the most favorable outcome with 5-year OS of 72.2%  9.8%. CONCLUSION: The outcome of @entity2828 @entity1 after a short aggressive course of chemotherapy (the MSKCC P6 protocol), is comparable to that following other first-line treatment regimens in use, with potentially fewer long-term adverse events.
